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Co-heritability of hypertension and insulin resistance (IR) within families not only implies
genetic susceptibility may be responsible for these complex traits but also suggests a
rational that biological candidate genes for hypertension may serve as markers for features
of the metabolic syndrome (MetS). Thus we determined whether the T323C polymor-
phism (rs5333) of endothelin type A (ETA) receptor, a predominant receptor evoking potent
vasoconstrictive action of endothelin-1, contributes to susceptibility to IR-associated hyper-
tension in 1694 subjects of Chinese and Japanese origins. Blood pressures (BPs) and
biochemistries were measured. Fasting insulin level, insulin-resistance homeostasis model
assessment (HOMAIR) score, and area under curve of insulin concentration (AUCINS) were
selected for assessing insulin sensitivity. Genotypes were obtained by methods of poly-
merase chain reaction-restriction fragment length polymorphism. Foremost findings were
that minor allele frequency of theT323C polymorphism was noticeable lower in our overall
Asian subjects compared to multi-national population reported in gene database; moreover
both the genotypic and allelic frequencies of the polymorphism were significantly different
between the two ethnic groups we studied. The genotype distributions at TT/TC/CC were
65, 31, 4% in Chinese and 51, 41, 8% in Japanese, respectively (p<0.0001). Additionally,
carriers of the C homozygote revealed characteristics of IR, namely significantly higher lev-
els of fasting insulin, HOMAIR score, and AUCINS at 29.3, 35.3, and 39.3%, respectively,
when compared to their counterparts with TT/TC genotypes in Chinese. Meanwhile, the
CC genotype was associated with a higher level of high density lipoprotein cholesterol in
Japanese. No association of the polymorphism with BP was observed. This study demon-
strated for the first time that T323C polymorphism of ETA receptor gene was associated
with an adverse insulin response in Chinese and a favorite atherogenic index in Japanese.
Keywords: ETA receptor,T323C polymorphism, metabolic syndrome, hypertension
Abbreviations: AUCINS, area under curve of insulin concentration; BMI, body mass
index; BP, blood pressure; CAP, College of American pathologists; CDC/NHLBI,
centers for disease control and prevention/national heart, lung, and blood institute;
CVD, cardiovascular disease; ET-1, endothelin-1; ETA receptor, endothelin type
A receptor; ETB receptor, endothelin type B receptor; ETS, endothelin system;
GWAS, genome-wide association studies; HDL, high density lipoprotein; HOMAIR,
insulin-resistance homeostasis model assessment; IR, insulin resistance; LDL, low
density lipoprotein; MetS, metabolic syndrome; OGTT, oral glucose tolerance test;
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INTRODUCTION
Insulin resistance (IR) and hypertension are related traits.
Individuals who are insulin resistant are glucose intolerant,
hyperinsulinemic, have higher blood pressure (BP) as well as
atherogenic dyslipidemia (1). The clustering of these cardiovas-
cular disease (CVD) risks associated with IR displayed familial
characteristics as well, often observed in diabetes and hypertension
families (2–5). For example, path analysis showed co-heritability
of BP and IR in Hispanic subjects with hypertension parents (6).
Cosegregation of traits in family not only reveals genetic suscep-
tibility but also implies genes contribute to one will predict other
traits in the family members. Therefore, biological candidate genes
for hypertension may serve as genetic markers for features of the
metabolic syndrome (MetS) (7). Dysfunction of endothelin sys-
tem (ETS) is one of ancillary clinical features of the MetS that could
lead to abnormalities in cardiovascular structure and function.
Endothelins are a family of three peptides of 21 amino acids
with strong vasoconstrictor effects (8, 9). Two receptors have been
cloned, endothelin type A (ETA) and endothelin type B receptor
(ETB) which bind the three endothelins with various affinities
(10). Endothelin-1 (ET-1) and nitric oxide are the prototypes
of endothelium-derived contracting factor and relaxing factor,
respectively, and their effects on the cardiovascular system have
been studied in depth (11–14). Experimental studies have pro-
vided evidence that ET-1 may exert a bidirectional vascular tonicity
effect either by vasodilation through enhancing nitric oxide pro-
duction via ETB receptors located in endothelial cells, or by vaso-
constriction via activating of ETA receptors prevalently located in
the vascular smooth muscle cells and/or blunting ETB receptors.
Moreover, findings from both clinical and animal studies are in
favor of a direct role of ET-1 in the pathogenesis of hypertension
(15). In addition, we and others have previously reported in ani-
mal and cellular experiments showing that ET-1 and ETA receptor
probably played a significant role in the pathogenesis of IR and its
association with hypertension (16–19). However, the link between
ETS and IR-associated hypertension in clinical settings remain to
be elucidated.
The diverse expression pattern of the ETS components is asso-
ciated with a complex pharmacology and its counteracting physi-
ological actions. New modulators of the ETS have been described:
retinoic acid (20), leptin (21), prostaglandins and hypoxia (22).
Endothelins can be considered as regulators working in paracrine
and autocrine fashion in a variety of organs in different cel-
lular types. They affect the physiology and pathophysiology of
the liver, muscle, skin, adipose tissue, and reproductive tract. In
contrast, the genetic determinants of ETS and their association
to the metabolic CVD risks have not been extensively studied.
Previous findings (23–30) on associations of some genetic poly-
morphisms of endothelins and their receptors with BP were con-
troversy; moreover, few features of MetS were ascertained in these
studies (30).
The present study was investigated to address the genetic poly-
morphism of ETA receptor in a large Chinese and Japanese cohort
PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism;
SAPPHIRe, Stanford Asian-Pacific program in hypertension and insulin resistance;
VLDL, very low density lipoprotein; WHR, waist/hip ratio.
with hypertensive proband. We hypothesized that ETA receptor,
a component of the ETS shown to play essential roles in the
maintenance of renal homeostasis and basal vascular tone, may
confer susceptibility to IR-related hypertension due to its multiple
expression sites and complex modulators. We demonstrated that
ETA receptor exon 6 T323C polymorphism (rs5333) was associ-
ated with IR and hyperinsulinemia in Chinese, and was related
with high density lipoprotein (HDL)-cholesterol and atherogenic
index in Japanese.
MATERIALS AND METHODS
STUDY SUBJECTS
Subjects in this current study were those for the Stanford Asian-
Pacific Program in Hypertension and Insulin Resistance (SAP-
PHIRe) genetic study that aimed at mapping genetic loci for
hypertension and IR in a well-characterized population regarding
IR and its related metabolic traits. The study design and subject
recruitment for SAPPHIRe were described in detail previously
(31). In brief, SAPPHIRe, a family based and sibling-paired design,
incorporated both concordant sibling pairs (i.e., two or more
hypertensive full siblings) and discordant sib-pairs (i.e., hyperten-
sive and hypo-normotensive siblings). Probands were hyperten-
sive individuals with Chinese or Japanese descent. The BP values
at the 80th percentile or more were considered as hypertension,
which was equivalent to systolic BP of at least 160 or diastolic BP of
at least 95 mmHg or taking two or more medications for high BP.
The hypo-normotensive sib controls was a combination of subjects
whose BP values below the bottom 30th percentile (i.e., hypoten-
sive) and whose BP not qualified for hyper- or hypotensive-status
(i.e., normotensive). In this particular study, we included in the
analysis only the non-diabetic subjects (fasting plasma glucose
<126 mg/dl) to reduce the confounding effect of hyperglycemia
on the quantitative measurements of glucose homeostasis. Conse-
quently, the study population genotyped comprised of 929 hyper-
tension and 765 hypo-normotension. Written informed consent
from all participants was obtained and the study protocol was
approved by the Institutional Review Board of each field center.
PHENOTYPIC AND BIOCHEMICAL CHARACTERIZATION
SAPPHIRe study incorporated physical examinations and anthro-
pometric measurements, routine clinical laboratory tests, an oral
glucose tolerance test (OGTT), and administration of an infor-
mative questionnaire to obtain biochemical data and phenotypic
information on subjects. Measurement protocols for BP and
anthropometry were previously reported in detail (5, 32). Body
mass index (BMI) was calculated as body weight in kilograms
divided by body height square in meters. A standard dose of 75-g
glucose monohydrate dissolved in water was administered to the
study subjects after an overnight fast. Venous blood was sampled
before and 1- and 2-h after oral glucose challenge, and plasma
was prepared by immediate centrifugation. Plasma glucose was
measured by a glucose oxidase method and plasma insulin was
determined using an enzymatic immunoassay. Concentrations of
fasting plasma glucose and insulin obtained from OGTT were
applied to calculate insulin-resistance homeostasis model assess-
ment (HOMAIR), a surrogate index for insulin sensitivity validated
to the reference method of the euglycemic hyperinsulinemic clamp
Frontiers in Endocrinology | Diabetes November 2013 | Volume 4 | Article 172 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ho et al. ETAR genotype and metabolic syndrome
(33), using the formula as described by Matthews et al. (34): fasting
insulin (µU/mL)× fasting plasma glucose (mmol/L)/22.5. High
HOMAIR scores denoted low insulin sensitivity, i.e., more insulin
resistant. Three surrogate indices, fasting insulin level, HOMAIR
score, area under curve of insulin concentration (AUCINS),
were selected for assessing insulin sensitivity. Clinical chemistries
included fasting concentrations on total cholesterol, triglycerides,
HDL cholesterol were determined by automated enzymatic meth-
ods using colorimetry as end point. Low density lipoprotein
(LDL)- and very low density lipoprotein (VLDL)-cholesterol were
calculated by Friedewald equation (35). All lipid determinations
were standardized with the centers for disease control and preven-
tion/national heart, lung, and blood institute (CDC/NHLBI) lipid
standardization program and further assured by participating in
the College of American pathologists (CAP) survey.
GENOTYPING OF ETA RECEPTOR GENE POLYMORPHISM
Using polymerase chain reaction (PCR) followed by restric-
tion fragment length polymorphism (RFLP) analysis, we deter-
mined the polymorphism of exon 6 codon 323 T→C in the
ETA receptor gene. The DNA fragment containing the poly-
morphism site was amplified using the forward primer 5′-
TTTCTCACTTTCCTTTAGCG-3′ and the reverse primer 5′-
ACCTAAGTAATTCACATCGG-3′. PCR amplifications were car-
ried out in a final volume of 30µL by 30 cycles at 94, 50, and
72°C each for 30 s and followed by a final extension step at 72°C
for 10 min. Blank controls containing no genomic DNA were
included in each run of PCR amplification to monitor contam-
ination. Agarose gel electrophoresis on randomly selected PCR
products was performed routinely to check if amplification suc-
ceeded. For subsequent RFLP analysis, the PCR product was mixed
with 1U AflII and 1µg/mL BSA in the appropriate buffer (New
England Biolabs, Beverly, MA, USA) and incubated at 37°C for 3 h
to ensure the complete enzyme digestion. The digested products
were separated by electrophoresis on 3% agarose gel, visualized
by ethidium bromide staining and analyzed under UV light. The
person who assessed the genotype was blinded to the clinical data
of the subjects from whom the samples originated. Direct DNA
sequencing using ABI PRISM377 machine together with BigDye™
Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer,
Applied Biosystems, Foster City, CA, USA) on randomly selected
PCR products from each genotype was also performed to validate
the polymorphisms.
The restriction enzyme AflII is specific for the sequence
C/TTAAG. Digestion of PCR product with AflII resulted in two
fragments of different sizes at 67 and 87 bp for the existence of
C allele. However, the restriction site is lost in the presence of T
variant, and therefore digestion products shown a single band at
154 bp. Thus, three genotypes TT, TC, and CC at codon 323 in
exon 6 of ETA receptor gene were defined according to numbers
of fragments by RFLP, depending on the presence of C allele as a
restriction site for AflII.
STATISTICAL ANALYSES
Data were expressed as the mean and the standard devia-
tion (mean± SD), unless otherwise specified. The ETA receptor
genotype distributions and allele frequencies between subjects
with different ethnicity and BP status were compared by Chi-
square analyses. The Hardy–Weinberg equilibrium was also exam-
ined using the Chi-square test. The association of the ETA receptor
gene variant with the variables of interest was assessed using mixed
model regression analyses as described previously (36), with famil-
ial effect controlled by adjusting for family clustering effect. The
mean differences of metabolic variables between siblings discor-
dant for the genotypes within families were further evaluated by
the delta method in which the potential family random effect was
eliminated (5, 36). Specifically, due to genetic dependence of sib-
lings, differences in the phenotypic traits with regard to genotypes
were compared by paired t tests, while pooling the T allele carriers
together, before and after adjusting for possible confounding vari-
ables including age, gender, and BMI. All analyses were performed
using the SAS statistical software package (SAS Institute Inc., Cary,
NC, USA), and tests were two-sided throughout and a p-value of
<0.05 was considered statistically significant.
RESULTS
The general characteristics of the participants categorized by eth-
nicity are shown in Table 1. No significant differences were found
in gender distribution and age onset for hypertension between the
two ethnic groups. Chinese subjects were somewhat younger in
age, had shorter duration in hypertension, and exhibited a smaller
waist girth and lower BMI, and waist/hip ratio (WHR) than the
Japanese. Japanese possessed elevated levels of blood lipids except
for LDL-cholesterol and resulted in a decreased ratio of total- to
HDL-cholesterol as compared to the Chinese. There were no con-
sistent differences in the glucose homeostasis parameters such as
fasting and postprandial glucose and insulin, and the surrogate
insulin indices.
A total of 1694 biethnic sibling subjects (1304 Chinese and
390 Japanese) deriving from eligible families were analyzed. The
genotype distributions in overall or each for Chinese and Japan-
ese were all in compliance with the Hardy–Weinberg equilibrium
(p= 0.166 for overall, p= 0.225 for Chinese, and p= 0.949 for
Japanese). Significant differences (p< 0.0001) on genotype fre-
quencies were observed between subjects with different ethnic
backgrounds (Table 2). The C homozygote was present only in
4.4% of the Chinese but nearly doubled in 8.5% of the Japanese,
whereas the more common T homozygote was at 64.9 and 50.5%
for Chinese and Japanese, respectively. The relative frequencies
of the T and C alleles of the ETA receptor gene in Chinese were
0.80 and 0.20, and in Japanese 0.71 and 0.29 (p< 0.0001). Neither
genotype nor allele frequency was different with respect to gender.
Moreover, there was no statistical significant difference in geno-
types concerning the BP status in our studied subjects despite the
anticipated role of ETA receptor in the regulation of cardiovascular
complications.
Due to the significant ethnic differences, we next evaluated
the association of genotypes of ETA receptor with the quanti-
tative traits of the MetS in each individual ethnicity. Using a
mixed model controlling for family effect, we observed associ-
ation of ETA receptor genotypes with fasting and postprandial
insulin concentrations, as well as HOMAIR and AUCINS indices
in Chinese population before and after adjusting for confound-
ing variables (Table 3). In the Japanese cohort, ETA receptor
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Table 1 |The anthropometric and metabolic characteristics of study population (mean±SD).
Variable Chinese N =1304 Japanese N =390 All subjects N =1694 p-Value
Age (year) 49.1±8.6 55.3±8.3 50.5±8.9 <0.0001
Gender (male/female, %) 44.8/55.2 41.0/59.0 43.9/56.1 NS
HTN [n, (%)] 663 (50.8) 266 (68.2) 929 (54.8) <0.0001
Age of HTN onset (year) 43.9±9.5 43.0±9.8 43.6±9.6 NS
Duration of HTN (year) 7.2±8.1 12.9±10.2 8.8±9.1 <0.0001
Waist (cm) 84.2±10.3 89.4±11.4 85.4±10.8 <0.0001
BMI (kg/m2) 25.2±3.4 26.4±3.9 25.5±3.6 <0.0001
WHR (cm/cm) 0.87±0.08 0.92±0.09 0.88±0.08 <0.0001
Blood pressure (mmHg)
Systolic 128.8±24.5 131.9±20.4 129.5±23.7 0.0316
Diastolic 76.9±13.5 77.6±11.6 77.1±13.2 NS
Lipid profiles (mg/dl)
Triglycerides 124.2±76.3 162.4±99.9 132.3±83.3 <0.0001
Total CHOL 187.3±38.6 200.0±36.3 190.0±38.5 <0.0001
HDL-cholesterol 44.3±12.2 49.9±14.8 45.5±13.0 <0.0001
VLDL-cholesterol 24.2±13.3 30.0±15.0 25.4±13.9 <0.0001
LDL-cholesterol 118.8±36.3 118.7±32.0 118.8±35.4 NS
Atherogenic index (CHOL/HDL) 4.5±1.5 4.3±1.3 4.5±1.4 0.0106
Oral glucose tolerance test
Plasma glucose (mg/dl)
Fasting 90.2±11.3 96.1±10.7 91.4±11.4 <0.0001
1-h 173.8±44.1 165.6±47.4 172.4±44.8 0.0090
2-h 138.8±44.2 140.3±43.6 139.1±44.1 NS
Plasma insulin (µIU/ml)
Fasting 7.6±5.5 7.2±5.0 7.6±5.4 NS
1-h 77.5±59.3 64.3±44.2 75.3±57.2 0.0010
2-h 66.7±60.1 65.5±51.2 66.5±58.5 NS
Insulin resistance indices
HOMAIR 1.8±1.4 1.8±1.3 1.8±1.4 NS
AUCINS (µIU/ml/h) 114.8±82.7 100.3±63.9 112.4±80.0 0.0100
HTN, hypertension; BMI, body mass index; WHR, waist-to-hip ratio; CHOL, cholesterol; HDL, high density lipoprotein; VLDL, very low density lipoprotein; LDL, low
density lipoprotein; HOMAIR, insulin-resistance homeostasis model assessment; AUCINS, area under curve of insulin concentration.
Table 2 | Distribution of genotypes and alleles for the ETART323C
polymorphism in studied subjects.
Subjects Genotype, n (%) Allele %
TT TC CC T C
Ethnicity*
Chinese 846 (64.9) 400 (30.7) 58 (4.4) 80.2 19.8
Japanese 197 (50.5) 160 (41.0) 33 (8.5) 71.0 29.0
BP status
Hypertension 556 (59.8) 323 (34.8) 50 (5.4) 77.2 22.8
Hypo-normotension 487 (63.6) 237 (31.0) 41 (5.4) 79.2 20.8
Overall subjects of
eligible families
1043 (61.6) 560 (33.0) 91 (5.4) 78.1 21.9
*p<0.0001.
genotype was significantly associated with the VLDL- and HDL-
cholesterol concentrations and consequently with the ratio of
total to HDL cholesterol (Table 4). The adjustment for age,
gender, and BMI did not affect the observations but strength-
ened the association seen in both Chinese and Japanese. To clearly
illustrate the discrete nature of the association of ETA recep-
tor genotype with MetS in Chinese and Japanese, comparisons
on the mean values of the quantitative traits with significant
differences were made and presented in Figure 1. Because the
initial cohort was ascertained as a family study, the genetic asso-
ciation of ETA receptor alleles with variables of the MetS was
further analyzed by delta method. The results were essentially
unchanged and these analyses further confirmed the association
of ETA receptor gene with the CVD risks of IR in Chinese (Data
not shown).
Since phenotypic expression of IR-associated hypertension is
diverse and bounded, we further performed correlation analysis
by treating the indices of insulin sensitivity as dependent variables,
and the potential contributors including the ETA receptor geno-
type, BMI, age, et cetera as independent variables. By this approach
we could predict if any attribute, while controlling for other covari-
ates, is independently associated with changes in the indices at all.
Results on the levels of significance in the pooled studied subjects
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Table 3 | Clinical characteristics of the Chinese siblings with discordant ETA receptor genotypes are compared with or without adjustment for
age, gender, and BMI (Mean±SD).
Traits Genotypes Unadjusted p-value Adjusted p-value
TT/TC CC
Subject number 1215 57
Blood pressure (mmHg)
Systolic 129.4±0.9 129.5±3.5 0.8799 0.9693
Diastolic 77.3±0.5 77.9±1.9 0.8995 0.7861
Lipid profiles (mg/dl)
Triglycerides 126.1±2.7 123.8±10.7 0.4184 0.8297
Total CHOL 187.8±1.5 188.1±5.3 0.6661 0.9580
HDL-cholesterol 43.7±0.4 43.3±1.5 0.0600 0.7614
VLDL-cholesterol 24.5±0.5 24.8±1.8 0.2227 0.9023
LDL-cholesterol 119.6±1.4 117.3±5.0 0.4414 0.6473
Atherogenic index (CHOL/HDL) 4.6±0.1 4.7±0.2 0.0951 0.4653
Oral glucose tolerance test
Plasma glucose (mg/dl)
Fasting 90.4±0.4 92.4±1.5 0.1395 0.1690
1-h 173.7±1.7 181.9±6.0 0.1148 0.1755
2-h 138.8±1.7 139.2±6.0 0.8998 0.9482
Plasma insulin (µIU/ml)
Fasting 7.5±0.2 9.7±0.6 0.0055 0.0007
1-h 76.9±2.1 107.7±8.3 0.0004 0.0003
2-h 68.1±2.4 94.3±8.3 0.0054 0.0017
Insulin resistance indices
HOMAIR 1.7±0.1 2.3±0.2 0.0070 0.0014
AUCINS (µIU/ml/h) 115.1±3.1 160.3±11.3 <0.0001 <0.0001
CHOL, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein, HOMAIR, insulin-resistance homeostasis model
assessment; AUCINS, area under curve of insulin concentration.
are present in Table 5. The correlations among interrelating IR
traits for example BMI and waist circumference showed signif-
icance as would be expected. In particular, we found that ETA
receptor T323C genotype was not only significantly (p= 0.0012)
but also independently from BMI, waist circumference, triglyc-
erides and HDL-cholesterol concentrations, and gender correlated
with the index of AUCINS. Additionally, we observed that waist cir-
cumference turned into a more significant predictor than WHR to
HOMAIR and AUCINS in our studied population.
DISCUSSION
Enhanced vascular gene expressions of ET-1 and ETA receptor, and
an amelioration of hypertension via administration of selective
ETA receptor antagonist observed previously in our fructose-
induced hypertensive rats (18) and in comprehensive reviews (15,
37, 38) suggested that ETA receptor may play a role in the reg-
ulation of BP and consequently its antagonists may become one
of the therapeutic strategies in clinical. To date, genetic variations
and association studies of this putative hypertension gene (23–
25, 29, 39) have been performed mostly in subjects of European
ancestry but not in Asian origins excepta few literature regarding
Japanese (26, 40). Therefore, we conducted this study to investigate
whether the T323C polymorphism of the gene encoded for ETA
receptor might be involved in the predisposition in IR-associated
hypertension in a large Asian cohort ascertained via essential
hypertension. The novel findings of this study are firstly the obser-
vation of noticeable lower minor allele frequency in our overall
Asian subjects compared to multi-national population reported
in gene database (http://www.genecards.org) at 0.22 and 0.35,
respectively. Secondly, an ethnic difference between Chinese and
Japanese we studied on the allele frequencies of the T323C variant
was identified. Thirdly, the ETA receptor T323C polymorphism
was associated with discrete features of the MetS in our two Asian
populations.
Although significant differences on the genotypic and allelic
frequencies of this T323C variant of the ETA receptor gene were
observed between our subjects of Chinese and Japanese origin, no
association of the T323C polymorphism with hypertension sta-
tus was seen in either Asian ethnic group, i.e., neither systolic nor
diastolic BP appeared to be influenced by the gene variant. Our
findings supported and extended the prior observations in Cau-
casians (23, 24, 29) that there is no significant association of this
solely gene polymorphism with BP. On the contrary, some other
polymorphisms of ETS have been shown to be associated with
BP either directly or in interaction with other genes/factors, for
example C1363T in exon 8 of the ETA receptor on pulse pressure
of normotension (24), G198T in exon 5 of the ET-1 gene together
with BMI on BP (26), and A985G in 3′-untranslated region of
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Table 4 | Effect of the ETA receptor genotypes on clinical characteristics of Japanese discordant siblings before and after adjustment for age,
gender, and BMI (Mean±SD).
Traits Genotypes Unadjusted p-value Adjusted p-value
TT/TC CC
Subject number 316 29
Blood pressure (mmHg)
Systolic 131.9±1.2 132.8±3.7 0.9057 0.8309
Diastolic 78.1±0.7 79.3±2.1 0.8858 0.6028
Lipid profiles (mg/dl)
Triglycerides 168.9±6.7 138.0±20.1 0.1486 0.1353
Total CHOL 198.9±2.4 199.4±6.9 0.8455 0.9426
HDL-cholesterol 48.4±0.9 54.9±2.6 0.0461 0.0155
VLDL-cholesterol 31.6±1.1 24.8±2.9 0.0450 0.0255
LDL-cholesterol 118.1±2.1 114.4±6.5 0.4378 0.5769
Atherogenic index (CHOL/HDL) 4.4±0.1 3.8±0.2 0.0273 0.0214
Oral glucose tolerance test
Plasma glucose (mg/dl)
Fasting 96.8±0.6 98.8±1.8 0.2310 0.2882
1-h 166.6±3.5 167.0±9.7 0.9227 0.9662
2-h 139.7±3.0 146.2±8.8 0.5161 0.4716
Plasma insulin (µIU/ml)
Fasting 7.3±0.3 6.1±0.8 0.6009 0.1256
1-h 63.1±3.0 65.4±9.1 0.4749 0.8081
2-h 63.4±3.1 59.7±9.5 0.9894 0.6996
Insulin resistance indices
HOMAIR 1.8±0.1 1.5±0.2 0.8718 0.2348
AUCINS (µIU/ml/h) 97.9±4.2 99.8±12.7 0.5342 0.8859
CHOL, cholesterol; HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; HOMAIR, insulin-resistance homeostasis model
assessment; AUCINS, area under curve of insulin concentration.
the ET-2 gene on the severity of hypertension (41). Moreover, one
association study reported a significant interaction of ETA recep-
tor T323C and ET-1 138 insertion/deletion polymorphisms on
diastolic BP in normotensive subjects (25).
Thus far, the predisposition of genes involved in ETS has been
illustrated in the CVD including hypertension (23, 25, 26, 41),
myocardial infarction (24), cardiomyopathy (39), and others (42).
To our knowledge, no study has been conducted to determine
the implication of the T323C polymorphism of ETA receptor
gene in IR, an intermediate metabolic phenotype for hyperten-
sion (43). Thus, we further explored the association of the ETA
receptor’s T323C polymorphism with the MetS related quantita-
tive traits. A noteworthy finding in our study was that Chinese
siblings who were carriers of the C homozygote, the rare allele of
ETA receptor T323C polymorphism, manifested characteristics of
IR, namely significantly higher levels of fasting insulin, HOMAIR
score, and AUCINS at 29.3, 35.3, and 39.3%, respectively, when
compared to their counterparts with TT/TC genotypes. Consistent
with the observation, results from regression analysis revealed that
the ETA receptor T323C genotype was a significant determinant
for AUCINS independent from confounders in our pooled Asian
population. Meanwhile, we observed that the CC genotype was
significantly associated with an increased level of HDL cholesterol
at 13.4% and consequently with a reduced ratio of Total/HDL
cholesterol in Japanese. The current findings suggested a recessive
effect of allele C in the ETA receptor T323C polymorphism on
an adverse insulin response in Chinese and a favorite atherogenic
index in Japanese.
Numerous studies provide convincing evidence that pheno-
typic aspects of MetS differ among ethnicities. Since MetS involves
a constellation of highly intercorrelated quantitative phenotypes,
factor analysis has been applied in attempts to simplify the risk
factors and to discover the underlying pathophysiological mecha-
nisms (44). Evaluation of the MetS in multi-ethnic groups includ-
ing the SAPPHIRe participants has shown that the identified factor
pattern was very similar in African Americans, Hispanics, Whites,
and Japanese, but not entirely so in Chinese (45). The common
factor, interpreted as obesity, explained the largest and compara-
ble portion of the overall variance in both the Chinese and the
Japanese though the factor loadings themselves were substantially
different in magnitude between the two ethnic groups. On the
other hand, insulin level was the major component of the second
factor and in together with other variables contributed nearly 17%
of the variance in Chinese, but insulin was merely an intermediate
component for Japanese. Conversely, the lipid factor, characterized
by a negative loading for HDL cholesterol, was more prominent
in Japanese than in Chinese. These results suggest ethnic vari-
ability in susceptibility to the specific risk factors of the MetS,
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FIGURE 1 | Effect of the ETA receptor genotypes on surrogate indices of
insulin sensitivity, HDL-cholesterol, and atherogenic index. -•- for
Chinese, -◦- for Japanese. Vertical lines represent SD. Significant
differences denote as *p<0.01, #p<0.05.
which strengthens our findings that the T323C polymorphism
was associated with not only the distinct but the more prominent
phenotype for each ethnic group. However, the mechanisms that
Table 5 | Results on the p-values of correlation analysis using insulin
sensitivity indices as dependent variables and insulin resistance
related traits and genotypes as independent variables.
Independent traits Dependent variable
HOMAIR AUCINS
ETA receptor genotype (TT+TC vs. CC) NS 0.0012
Covariate
Blood pressure NS NS
Body mass index <0.0001 <0.0001
Waist-to-hip ratio NS NS
Waist 0.0002 0.0008
Triglycerides <0.0001 <0.0001
HDL-cholesterol <0.0001 <0.0001
LDL-cholesterol NS NS
VLDL-cholesterol NS NS
Age NS NS
Gender 0.0001 0.0001
HOMAIR, insulin-resistance homeostasis model assessment; AUCINS, area under
curve of insulin concentration.
this ETA receptor T323C polymorphism might exert its opposite
influence on MetS in different racial people are not yet elucidated
in this study.
Human genome contains a single copy of the ETA receptor
gene which spans over 64 kb on chromosome 4q31.22 and com-
prises eight exons and seven intros. Though examining sole single
nucleotide polymorphism might have limitations of interpreta-
tion, study on combination of four common haplotype blocks
merely revealed mild effect on the risk of hypertension (29).
It should be noted that this variant located within codon 323
in the sixth exon of ETA receptor gene is a silent polymor-
phism (CAT→CAC, His→His). As a silent polymorphism which
nucleotide substitution on the third base of the codon does not
alter the amino acid sequence of the receptor protein, it is unlikely
that the variant itself is involved in the pathophysiology of MetS.
One possibility for this silent polymorphism exerts its influence
is that it is in linkage disequilibrium with a nearby causal variant
which has not yet been identified. In addition, the wobble base pair
is a fundamental unit for RNA secondary and tertiary structures
and therefore may have functional consequences. Without further
RNA studies, the possibility of unrecognized alleles, disrupting
exonic splicing enhancers, and/or influencing gene transcription
cannot be excluded. Although BP and IR have been shown to
cosegregate in Hispanic families with a hypertensive proband
(6), no correlation was observed between BP and insulin sensi-
tivity index in our Asian subjects. The lack of relationship may
partially be due to the fact that the measurement of BP of the
hypertensive individuals in SAPPHIRe study was confounded by
medication since majority of our hypertensive subjects were on
antihypertensive treatment. In addition, our BP measurements
feasible for large-scale study may not be sensitive enough as 24 h
ambulatory recordings, a necessary tool to identify a relationship
between BP and IR within the hypertensive range suggested by
Nilsson et al. (46).
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Beyond candidate genes in ETS for the predisposition of IR-
associated hypertension, the notion of using biological candidate
genes for interrelating traits as genetic markers for the features
of MetS and/or diabetes has also been applied in other studies
regardless successes or not. For example, Bayoglu et al. identified
polymorphism rs10757278 on chromosome 9p21 which is risk
locus for coronary artery disease may confer increased risk for
MetS in Turkish people (47). Ned et al. merely found marginal
association between inflammation-related genes and the suscep-
tibility of albuminuria (48), and Moon et al. on the other hand,
were unable to relate polymorphisms of pyruvate dehydrogenase
kinase four gene, a mitochondrial kinase attributing to hyper-
glycemia, with MetS or diabetes in Korean (49). One example
of linking candidate gene deletion in mice with a polymorphism
association study in patients with hypertension has shown that
rs10491334 of calcium/calmodulin-dependent kinase IV gene may
play a pivotal role in hypertension via the regulation of endothelial
nitric oxide synthase (50). Another example of candidate geno-
type polymorphism in a small sample sized population with a
replication of another same ethnic population revealed a signif-
icant association of the platelet antigen variant of glycoprotein
IIIa (PIA1/A2) with stroke in a sub-group of high risk hypertension
patients (51). Moreover, recent genome-wide association studies
(GWAS) have identified susceptibility loci for various compo-
nent traits of MetS including lipid/lipoprotein profiles (52, 53)
and obesity (54), or for MetS as an entity in European ances-
try (52, 55) and Indian Asian (56). Given these research findings
affirm the multifactorial aetiology and multigenic nature of MetS.
However, these GWAS approach in combination with either bi-
or multi-variate haplotypes done in Asian ethnic’s remains to
be seen (55). A trans-ethnic GWAS with fine mapping of these
genotypes with optimal sample size may find population specific
associations (57) and a similar replication study conducted in a
separate Chinese–Japanese population may be advised in further
works (58).
In conclusion, we have successfully related the T323C poly-
morphism of ETA receptor gene to features of MetS in this study
though no association between the gene variant and BP is reassur-
ing in our hypertensive subjects of Chinese and Japanese origin.
Our findings can be considered as the first time to be related
directly to IR, and also the first in Asian populations despite its
dissociated effects on different ethnicities. If reproducible in other
independent ethnicities, our results reported herein suggest that
the polymorphism of ETA receptor gene may serve as one of
the independent determinants for manifested IR which is often
a prelude to hypertension. Nevertheless, the functional signifi-
cance of this particular gene variant, the inference on haplotype
effects, and the gene–gene/gene-environment interactions remain
to be elucidated. Determinants of CVD risk in diabetes beyond
hyperglycemia has been an important issue to address lately, since
intensive control of plasma sugar alone is often insufficient to
reduce the incidence of major CVD in these patients (59). Com-
ponents of MetS and many other CVD risk factors including those
with pro-inflammatory, pro-thrombotic, and/or oxidative stress
effects all need to be considered and tackled in addition to con-
trol of hyperglycemia. Among them, ET-1, the key member of
ETS, by playing multiple roles relating IR, hypertension, as well as
proliferative and pro-inflammatory effects may be a perspective
target for drugs discovery and/or other intervention modalities
useful not only for management but prevention of MetS, diabetes
mellitus and related CVD (38).
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